Skip to main content

Table 1 Distribution of C6 rat glioma cells in different phases of the cell cycle under treatment for 24 h with 4-thiazolidinone derivatives Les-3288 and Les-3833 in free form and in complex with polymeric nanocarrier (PNC)

From: Enhanced Proapoptotic Effects of Water Dispersed Complexes of 4-Thiazolidinone-Based Chemotherapeutics with a PEG-Containing Polymeric Nanocarrier

Sample Number of cells in each cell cycle phase, mean ± SD
  Pre-G1 G 1 S G2/M
Control 3.52 ± 0.67 75.06 ± 0.57 11.61 ± 0.22 10.82 ± 1.21
PNC 0.1 μg/mL 3.30 ± 0.44 76.03 ± 0.52 13.33 ± 0.41 8.81 ± 0.92
PNC 0.5 μg/mL 5.78 ± 0.51 61.30 ± 0.50*** 12.07 ± 0.12 16.06 ± 0.18
Les-3288 0.1 μg/mL 2.81 ± 0.45 75.99 ± 0.06 12.01 ± 0.43 10.32 ± 1.10
Les-3288 0.5 μg/mL 5.99 ± 0.54* 63.33 ± 0.67*** 16.09 ± 0.12*** 15.19 ± 0.43***
Les-3288 + PNC
0.1 μg/mL
3.27 ± 0.31 73.54 ± 0.39 12.48 ± 1.20 11.44 ± 0.40
Les-3288 + PNC
0.5 μg/mL
24.89 ± 1.49 47.65 ± 0.34 9.77 ± 0.53 16.45 ± 0.16
Les-3833 0.1 μg/mL 3.06 ± 0.45 72.99 ± 0.84* 12.92 ± 1.11 12.07 ± 0.31
Les-3833 0.5 μg/mL 2.88 ± 0.67 72.53 ± 1.09** 13.23 ± 0.56 12.64 ± 0.41
Les-3833+PNC
0.1 μg/mL
9.11 ± 0.53### 54.86 ± 0.57### 17.40 ± 0.61 19.55 ± 1.41#
Les-3833+PNC
0.5 μg/mL
18.69 ± 1.71§§§ 53.42 ± 0.21§§§ 12.30 ± 0.55 15.32 ± 1.91
  1. Data are presented as mean ± SD
  2. *P < 0.05 related to control, **P < 0.01 related to control, ***P < 0.001 related to control, P < 0.001 related to Les-3288, 0.5 μg/mL, #P < 0.01 related to Les-3833, 0.1 μg/mL, ###P < 0.001 related to Les-3833, 0.1 μg/mL, §P < 0.05 related to Les-3833, 0.5 mg/mL, §§§P < 0.001 related to Les-3833, 0.5 mg/mL